Johannes Doll - Sedana Medical CEO Pres
| SEDANA Stock | SEK 11.96 0.30 2.45% |
Insider
Johannes Doll is CEO Pres of Sedana Medical AB
| Age | 42 |
| Phone | 46 8 12 40 52 00 |
| Web | https://www.sedanamedical.com |
Sedana Medical Management Efficiency
The company has return on total asset (ROA) of (0.0736) % which means that it has lost $0.0736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0689) %, meaning that it generated substantial loss on money invested by shareholders. Sedana Medical's management efficiency ratios could be used to measure how well Sedana Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Prof MD | Bonesupport Holding AB | 80 | |
| Fergus MacLeod | Bonesupport Holding AB | 53 | |
| Anders Larsson | Surgical Science Sweden | 50 | |
| Edward Holden | Swedencare publ AB | 42 | |
| Jeffrey Berkley | Surgical Science Sweden | 54 | |
| Daniel Evestedt | Surgical Science Sweden | 46 | |
| Ioanna Psychogiou | Swedencare publ AB | 38 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Martin Jansson | Surgical Science Sweden | 52 | |
| Hkan Johansson | Bonesupport Holding AB | 60 | |
| Matthew Shaw | Swedencare publ AB | 39 | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Kristina Ingvar | Bonesupport Holding AB | 51 | |
| MSc MD | Oncopeptides AB | N/A | |
| Jenny Graflind | Swedencare publ AB | 47 | |
| Adv | Surgical Science Sweden | 55 | |
| AnnMarie Thor | Bonesupport Holding AB | N/A | |
| Inbal MazorBadichi | Surgical Science Sweden | 54 | |
| Emil Billbck | Bonesupport Holding AB | 53 | |
Management Performance
| Return On Equity | -0.0689 | |||
| Return On Asset | -0.0736 |
Sedana Medical AB Leadership Team
Elected by the shareholders, the Sedana Medical's board of directors comprises two types of representatives: Sedana Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sedana. The board's role is to monitor Sedana Medical's management team and ensure that shareholders' interests are well served. Sedana Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sedana Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anders Ersson, Head Markets | ||
| Peter MD, Chief Officer | ||
| Clarisa Mogolln, Head Marketing | ||
| Linda Frln, Head Fin | ||
| Karolina LLM, G Counsel | ||
| Johannes Doll, CEO Pres | ||
| Johan Spetz, Chief Officer | ||
| Peter Froberg, Chief Officer |
Sedana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sedana Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0689 | |||
| Return On Asset | -0.0736 | |||
| Profit Margin | (0.41) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.4 B | |||
| Shares Outstanding | 99.34 M | |||
| Shares Owned By Insiders | 34.90 % | |||
| Shares Owned By Institutions | 37.82 % | |||
| Price To Book | 1.94 X | |||
| Price To Sales | 16.06 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Sedana Stock
Sedana Medical financial ratios help investors to determine whether Sedana Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sedana with respect to the benefits of owning Sedana Medical security.